NRX Pharmaceuticals (NRXP) Interest & Investment Income (2022 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Interest & Investment Income of $5000.0 for Q1 2026, up 25.0% year-over-year from $4000.0 in Q1 2025, and up 25.0% quarter-over-quarter from $4000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Interest & Investment Income (2022 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Interest & Investment Income for 5 consecutive years, with $5000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 25.0% year-over-year to $5000.0; the TTM figure through Mar 2026 stood at $13000.0 (down 38.1% YoY), while the FY2025 annual figure was $12000.0, down 72.73% from the prior year.
- Interest & Investment Income grew to $5000.0 in Q1 2026 per NRXP's latest filing, from $4000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $145000.0 in Q2 2023 and bottomed at $2000.0 in Q2 2025.
- Historically, Interest & Investment Income has averaged $40687.5 across 5 years, with a median of $6500.0 in 2024.
- On a YoY basis, Interest & Investment Income climbed as much as 575.0% in 2024 and fell as far as 95.17% in 2024.
- NRX Pharmaceuticals' Interest & Investment Income stood at $130000.0 in 2022, then sank by 43.08% to $74000.0 in 2023, then tumbled by 94.59% to $4000.0 in 2024, then changed by 0.0% to $4000.0 in 2025, then climbed by 25.0% to $5000.0 in 2026.
- Business Quant data shows NRXP's Interest & Investment Income at $5000.0 in Q1 2026, $4000.0 in Q4 2025, and $2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | 4,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | 119,000.00 |
| Jun 30, 2023 | 145,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | 130,000.00 |
| Sep 30, 2022 | 95,000.00 |
| Jun 30, 2022 | 23,000.00 |